Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Wednesday, 10 February 2021 09:15

Jennifer Carlisle

Written by

Board certified in internal medicine, hematology, and medical oncology, Jennifer W. Carlisle, MD is an Assistant Professor of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Carlisle received her medical degree from the University of Florida College of Medicine and completed her internal medicine residency at Washington University in Saint Louis and Barnes Jewish Hospital.  She then completed fellowship in Hematology and Medical Oncology at Emory University, where she was elected chief fellow. Dr. Carlisle is a member of the Discovery and Developmental Therapeutics Program and an active investigator in Emory’s Lung Cancer Spore grant from the National Cancer Institute. Her research interests include advancing understanding of immunotherapies and developing new therapies for lung cancer.

Wednesday, 10 February 2021 09:15

Ross Camidge

Written by
Director of Thoracic Oncology, University of Colorado
Wednesday, 10 February 2021 09:15

Lauren Byers

Written by
Lauren Averett Byers, MD, MS is an Associate Professor and physician-scientist in the Department of Thoracic and Head and Neck Medical Oncology and an Andrew Sabin Family Fellow at MD Anderson Cancer Center in Houston, Texas.  She completed her B.A. degree in Molecular Biology at Princeton University, her M.D. at Baylor College of Medicine, and M.S. in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences.  She is a member of the National Cancer Institute’s Small Cell Lung Cancer (SCLC) Consortium and serves on the NCI’s Thoracic Malignancy Steering Committee and SCLC Working Group.

Dr. Byers’ laboratory is focused on the molecular profiling of small cell lung cancer and the development of new treatments and predictive biomarkers, particularly as they pertain to drugs targeting DNA damage repair (DDR) and immunotherapy. As a direct extension of work completed in her lab, she has led multiple clinical trials for patients with lung cancer. In addition to an outstanding publication record of over 100 peer reviewed manuscripts, Dr. Byers has earned multiple honors including two AACR The Best of AACR Journals Awards and the MD Anderson President’s Recognition for Faculty Excellence - Research Excellence Award.
Wednesday, 10 February 2021 09:15

Paul A. Bunn, Jr.

Written by
Paul A. Bunn Jr., MD, is a Distinguished Professor of Medicine and the James Dudley Endowed Professor of Lung Cancer at the University of Colorado School of Medicine. He is the principal investigator of the SPORE in Lung Cancer grant at the University of Colorado, which aims to support translational research in lung cancer. Dr. Bunn has dedicated his career to identifying novel diagnostics and treatment strategies for lung cancer and improving the outcomes of patients with lung cancer.
Wednesday, 10 February 2021 09:15

Paul A. Bunn, Jr.

Written by
Paul A. Bunn Jr., MD, is a Distinguished Professor of Medicine and the James Dudley Endowed Professor of Lung Cancer at the University of Colorado School of Medicine. He is the principal investigator of the SPORE in Lung Cancer grant at the University of Colorado, which aims to support translational research in lung cancer. Dr. Bunn has dedicated his career to identifying novel diagnostics and treatment strategies for lung cancer and improving the outcomes of patients with lung cancer.
Wednesday, 10 February 2021 09:15

Julie Brahmer

Written by
Julie R. Brahmer, MD, MSc, is the Director of the Upper Aerodigestive Cancers Program, Co-Director of the Cancer Immunology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus. Dr. Brahmer is an international leader in lung cancer clinical trials research with particular expertise in drug development for thoracic malignancies and immunotherapy. She led the first in human trial of MDX-1106, now known as nivolumab and has been a leader in the development of immunotherapy for the treatment of non-small cell lung cancer.
Wednesday, 10 February 2021 09:15

Jeffrey Bradley

Written by
Dr. Jeffrey Bradley is the James W. Keller Distinguished Professor of Radiation Oncology and currently serves as the interim department chair. His clinical interest is in the management of thoracic malignancies. He serves as chair of the NRG Oncology Lung Cancer Committee and has many publications related to the therapy of lung cancer.
Wednesday, 10 February 2021 09:15

Penelope Bradbury

Written by
Dr. Penelope Bradbury is a staff medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada; Associate Professor, Department of Medicine, University of Toronto, Canada. After obtaining her medical degree from the University of Cardiff, UK and fellow of Royal Australasian College of Physicians, she undertook postgraduate fellowships at Princess Margaret Cancer Centre and the Canadian Cancer Trials Group, ON, Canada. Dr. Bradbury’s main research interest is in the field of clinical trials for thoracic cancer. Before joining the Princess Margaret Cancer Centre, she held the position of a senior investigator within the Canadian Cancer Trials Group for the thoracic and investigational new drugs program, during which time she held a Cancer Care Ontario Research Chair in Experimental Therapeutics. Dr. Bradbury is the current chair of the Canadian Cancer Trials Group Thoracic Disease Site Committee and is a recipient of the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award.
Wednesday, 10 February 2021 09:15

Hossein Borghaei

Written by
Chief of Thoracic Medical Oncology
Professor, Department of Oncology/Hematology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Wednesday, 10 February 2021 09:15

Collin Blakely

Written by
Dr. Blakely is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF. His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR-, and ALK-targeted therapies, and identifying new targets for molecular-directed therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.
Page 369 of 371